Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00482391
Status:
COMPLETED
Last Update Posted:
2017-05-12
First Post:
2007-06-04
Brief Title:
Doxorubicin and Cyclophosphamide Followed by Paclitaxel Trastuzumab and Lapatinib in Treating Patients With HER2Neu-Overexpressed Breast Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide AC Followed by Weekly Paclitaxel With Trastuzumab and Lapatinib in HER2NEU-OverexpressedAmplified Breast Cancer Feasibility
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to study a new treatment for HER-2neu breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MSKCC-07013 | None | None | None |